• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group.家族性高胆固醇血症患者发生致命性冠心病的风险。代表西蒙·布鲁姆登记组的科学指导委员会
BMJ. 1991 Oct 12;303(6807):893-6. doi: 10.1136/bmj.303.6807.893.
2
Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group.经治疗的杂合子家族性高胆固醇血症患者的死亡率:对临床管理的启示。代表西蒙·布鲁姆登记组的科学指导委员会。
Atherosclerosis. 1999 Jan;142(1):105-12.
3
Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register.治疗性家族性高胆固醇血症患者的冠心病死亡率:英国西蒙布鲁姆家族性高胆固醇血症登记处的更新。
Atherosclerosis. 2018 Jul;274:41-46. doi: 10.1016/j.atherosclerosis.2018.04.040. Epub 2018 May 1.
4
Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register.西蒙布鲁姆注册研究中严重与非严重家族性高胆固醇血症患者的冠心病死亡率。
Atherosclerosis. 2019 Feb;281:207-212. doi: 10.1016/j.atherosclerosis.2018.11.014. Epub 2018 Nov 12.
5
Sex differences in cardiovascular morbidity associated with familial hypercholesterolaemia: A retrospective cohort study of the UK Simon Broome register linked to national hospital records.家族性高胆固醇血症相关心血管疾病发病率的性别差异:一项对与国家医院记录相链接的英国西蒙·布鲁姆登记册的回顾性队列研究。
Atherosclerosis. 2020 Dec;315:131-137. doi: 10.1016/j.atherosclerosis.2020.10.895. Epub 2020 Oct 31.
6
Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry study.经治疗的黄色瘤性与非黄色瘤性杂合子家族性高胆固醇血症患者致命性冠心病风险的比较:一项前瞻性登记研究
Atherosclerosis. 2003 Sep;170(1):73-8. doi: 10.1016/s0021-9150(03)00233-8.
7
Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study.他汀类药物治疗杂合子家族性高胆固醇血症患者的全因、癌症和冠心病死亡率降低:一项前瞻性登记研究。
Eur Heart J. 2008 Nov;29(21):2625-33. doi: 10.1093/eurheartj/ehn422. Epub 2008 Oct 7.
8
Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.高胆固醇血症筛查与家族性高胆固醇血症病例发现:系统评价与成本效益分析
Health Technol Assess. 2000;4(29):1-123.
9
Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia.其他风险因素影响杂合子家族性高胆固醇血症的超额死亡率。
Atherosclerosis. 2000 Apr;149(2):421-5. doi: 10.1016/s0021-9150(99)00336-6.
10
Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study.经治疗的杂合子家族性高胆固醇血症患者的非冠心病死亡率和致命性癌症风险:一项前瞻性登记研究
Atherosclerosis. 2005 Apr;179(2):293-7. doi: 10.1016/j.atherosclerosis.2004.10.011. Epub 2004 Dec 8.

引用本文的文献

1
One Shock, Not One Cure: Electroporation Reveals Disease-Specific Constraints in Hepatocyte Gene Editing Therapy.一次电击,而非一种疗法:电穿孔揭示了肝细胞基因编辑疗法中特定疾病的限制因素。
Biology (Basel). 2025 Aug 20;14(8):1091. doi: 10.3390/biology14081091.
2
Efficacy, safety and cost-effectiveness of 40 mg versus 80 mg atorvastatin in a Sri Lankan cohort with acute coronary syndrome: a protocol for a single-centre randomised controlled clinical trial.在斯里兰卡急性冠状动脉综合征队列中,40毫克与80毫克阿托伐他汀的疗效、安全性和成本效益:一项单中心随机对照临床试验方案。
Trials. 2025 Sep 1;26(1):326. doi: 10.1186/s13063-025-08943-2.
3
Integrating New Technologies in Lipidology: A Comprehensive Review.脂质学中新技术的整合:全面综述
J Clin Med. 2025 Jul 14;14(14):4984. doi: 10.3390/jcm14144984.
4
Familial Hypercholesterolemia Mimicking Rheumatoid Arthritis: A Rare Case From Pakistan.模仿类风湿关节炎的家族性高胆固醇血症:来自巴基斯坦的罕见病例。
Cureus. 2025 Jun 17;17(6):e86207. doi: 10.7759/cureus.86207. eCollection 2025 Jun.
5
Cardiovascular disease and compliance with lipid-lowering therapy among young individuals with familial hypercholesterolemia in Norway - A register study.挪威家族性高胆固醇血症年轻个体的心血管疾病与降脂治疗依从性——一项登记研究
Am J Prev Cardiol. 2025 Jun 18;23:101043. doi: 10.1016/j.ajpc.2025.101043. eCollection 2025 Sep.
6
Sex and racial differences in prevalence and clinical characteristics of people living with LDLR and PCSK9 familial hypercholesterolemia genetic variants: Data from the All of Us Research program.携带低密度脂蛋白受体(LDLR)和前蛋白转化酶枯草溶菌素9(PCSK9)家族性高胆固醇血症基因变异人群的患病率及临床特征的性别和种族差异:来自“我们所有人”研究项目的数据
Am J Prev Cardiol. 2025 Jun 1;22:101024. doi: 10.1016/j.ajpc.2025.101024. eCollection 2025 Jun.
7
Role of Next-Generation Sequencing in Diagnosis of Familial Hypercholesterolemia in Serbia.下一代测序在塞尔维亚家族性高胆固醇血症诊断中的作用
Diagnostics (Basel). 2025 May 12;15(10):1212. doi: 10.3390/diagnostics15101212.
8
Transition of care from childhood/adolescence to adulthood in familial hypercholesterolemia.家族性高胆固醇血症患者从儿童期/青少年期到成年期的护理过渡
J Pediatr Endocrinol Metab. 2025 May 6. doi: 10.1515/jpem-2025-0127.
9
Genetic Determinants of the Familial Hypercholesterolaemia Phenotype.家族性高胆固醇血症表型的遗传决定因素
Ann Hum Genet. 2025 Sep;89(5):293-304. doi: 10.1111/ahg.12594. Epub 2025 Apr 2.
10
A strategy to increase identification of patients with Familial Hypercholesterolemia: Application of the Simon Broome lipid criteria in a large-scale retrospective analysis.一种提高家族性高胆固醇血症患者识别率的策略:西蒙·布鲁姆血脂标准在大规模回顾性分析中的应用。
Am J Prev Cardiol. 2025 Jan 9;21:100930. doi: 10.1016/j.ajpc.2025.100930. eCollection 2025 Mar.

本文引用的文献

1
Coronary disease in familial hypercholesterolemia.
Circulation. 1967 Jul;36(1):77-82. doi: 10.1161/01.cir.36.1.77.
2
Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia.
Circulation. 1974 Mar;49(3):476-88. doi: 10.1161/01.cir.49.3.476.
3
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.无需使用制备性超速离心机来估算血浆中低密度脂蛋白胆固醇的浓度。
Clin Chem. 1972 Jun;18(6):499-502.
4
Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states.家族性高脂蛋白血症状态下缺血性心脏病的风险
Lancet. 1969 Dec 27;2(7635):1380-2. doi: 10.1016/s0140-6736(69)90930-1.
5
Cohort study analysis with a FORTRAN computer program.使用FORTRAN计算机程序进行队列研究分析。
Int J Epidemiol. 1986 Mar;15(1):134-7. doi: 10.1093/ije/15.1.134.
6
Blood lipid concentrations and other cardiovascular risk factors: distribution, prevalence, and detection in Britain.血脂浓度及其他心血管危险因素:在英国的分布、患病率及检测情况
Br Med J (Clin Res Ed). 1988 Jun 18;296(6638):1702-6. doi: 10.1136/bmj.296.6638.1702.
7
Cholesterol screening programmes: how much potential benefit?胆固醇筛查项目:潜在益处有多少?
BMJ. 1989 Sep 2;299(6699):606-7. doi: 10.1136/bmj.299.6699.606.
8
Who should have their cholesterol concentration measured? What experts in the United Kingdom suggest.谁应该测量胆固醇浓度?英国专家给出的建议。
BMJ. 1989 Jun 17;298(6688):1615-6. doi: 10.1136/bmj.298.6688.1615.
9
Who is for cholesterol testing? Test selectively those who will benefit most.谁适合进行胆固醇检测?有选择地检测那些将最受益的人。
BMJ. 1989 Jun 17;298(6688):1593-4. doi: 10.1136/bmj.298.6688.1593.
10
AIDS and 'ordinary heterosexual people'.艾滋病与“普通异性恋者”。
BMJ. 1990 Jul 21;301(6744):138.

家族性高胆固醇血症患者发生致命性冠心病的风险。代表西蒙·布鲁姆登记组的科学指导委员会

Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group.

出版信息

BMJ. 1991 Oct 12;303(6807):893-6. doi: 10.1136/bmj.303.6807.893.

DOI:10.1136/bmj.303.6807.893
PMID:1933004
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1671226/
Abstract

OBJECTIVES

(a) To determine the excess mortality from all causes and from coronary heart disease in patients with familial hypercholesterolaemia; (b) to examine how useful various criteria for selective measurement of cholesterol concentration in cardiovascular screening programmes are in identifying these patients.

DESIGN

Prospective cohort study.

SETTING

Eleven hospital outpatient lipid clinics in the United Kingdom.

PATIENTS

282 men and 244 women aged 20-74 with heterozygous familial hypercholesterolaemia.

MAIN OUTCOME MEASURE

Standardised mortality ratio, all adults in England and Wales being taken as standard (standardised mortality ratio = 100 for standard population).

RESULTS

The cohort was followed up for 2234 person years during 1980-9. Fifteen of the 24 deaths were due to coronary heart disease, giving a standardised mortality ratio of 386 (95% confidence interval 210 to 639). The excess mortality from this cause was highest at age 20-39 (standardised mortality ratio 9686; 3670 to 21,800) and decreased significantly with age. The standardised mortality ratio for all causes was 183 (117 to 273) and also was highest at age 20-39 (standardised mortality ratio 902; 329 to 1950). There was no significant difference between men and women. Criteria for measurement of cholesterol concentration in cardiovascular screening programmes (family history, presence of myocardial infarction, angina, stroke, corneal arcus, xanthelasma, obesity, hypertension, diabetes, or any of these) were present in 78% of patients.

CONCLUSIONS

Familial hypercholesterolaemia is associated with a substantial excess mortality from coronary heart disease in young adults but may not be associated with a substantial excess mortality in older patients. Criteria for selective measurement of cholesterol concentration in cardiovascular screening programmes identify about three quarters of patients with the clinically overt condition.

摘要

目的

(a) 确定家族性高胆固醇血症患者各种原因及冠心病所致的超额死亡率;(b) 研究心血管筛查项目中用于选择性测量胆固醇浓度的各种标准在识别这些患者方面的有用程度。

设计

前瞻性队列研究。

地点

英国的11家医院门诊脂质诊所。

患者

282名男性和244名女性,年龄在20 - 74岁,患有杂合子家族性高胆固醇血症。

主要观察指标

标准化死亡率,以英格兰和威尔士的所有成年人作为标准(标准人群的标准化死亡率 = 100)。

结果

该队列在1980 - 1989年期间接受了2234人年的随访。24例死亡中有15例死于冠心病,标准化死亡率为386(95%置信区间210至639)。该病因导致的超额死亡率在20 - 39岁时最高(标准化死亡率9686;3670至21800),并随年龄显著下降。所有原因的标准化死亡率为183(117至273),同样在20 - 39岁时最高(标准化死亡率902;329至1950)。男性和女性之间无显著差异。心血管筛查项目中测量胆固醇浓度的标准(家族史、心肌梗死、心绞痛、中风、角膜弓、睑黄瘤、肥胖、高血压、糖尿病或上述任何一项)在78%的患者中存在。

结论

家族性高胆固醇血症与年轻成年人冠心病所致的大量超额死亡率相关,但在老年患者中可能与大量超额死亡率无关。心血管筛查项目中选择性测量胆固醇浓度的标准可识别约四分之三临床症状明显的患者。